ReviewFrontiers in bioengineering and biotechnology2026
Reactive oxygen species in skin diseases: pathogenic mechanisms and nanomaterial-based therapeutic strategies.
Review in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- GC-MS Profiling, Antioxidant and Enzyme Inhibitory Activities of Basil (Molecules (Basel, Switzerland) · 2026Article
- Digital Exposure and Skin Health in Children and Adolescents: A State-of-the-Art Review.Cureus · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Reactive oxygen species (ROS) are inevitable by-products of aerobic metabolism and play a dual role in skin physiology and pathology. At physiological levels, ROS act as essential second messengers regulating cellular signaling and maintaining skin homeostasis. However, excessive ROS accumulation disrupts redox balance, leading to oxidative stress, inflammation, barrier dysfunction, and macromolecular damage, which are closely associated with the pathogenesis of various skin diseases, including psoriasis, atopic dermatitis, pigmentary disorders, photoaging, and skin cancers. In recent years, increasing attention has been directed toward nanomaterial-based strategies for precise ROS regulation, owing to their unique physicochemical properties, such as high surface area, tunable antioxidant activity, and enhanced skin permeability. Compared with conventional antioxidants, nanomaterials, including nanozymes, metal-based nanoparticles, biomacromolecular nanomaterials, and ROS-responsive nanocarriers, exhibit superior stability, targeted delivery capability, and sustained therapeutic efficacy. These nanoplatforms can not only efficiently scavenge excessive ROS but also modulate redox-sensitive signaling pathways, inflammatory responses, and skin barrier repair in a disease-specific manner. This review systematically summarizes the core mechanisms by which ROS contribute to the development of skin diseases, with an emphasis on oxidative stress mediated inflammation, macromolecular damage, and barrier impairment. Furthermore, we comprehensively discuss recent advances in nanomaterial-based therapeutic approaches for ROS regulation, highlighting self-therapeutic nanozymes, biomacromolecular antioxidant materials, and antioxidant-loaded nanodelivery systems. Finally, current challenges and future perspectives for the clinical translation of ROS-targeted nanotherapies in dermatology are discussed, aiming to provide a theoretical basis for the rational design of next-generation nanomedicines for skin disease treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.